secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001528287-26-000008
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace Q4 rev $26.6M (+24%), FY25 rev $100M (+25%); guides FY26 $98-100M
---------------------------------------------------------------------------

- Q4 2025 revenue $26.6M (+24% YoY); RNS System revenue $22.4M (+26% YoY); gross margin 77.4%.
- Full year 2025 revenue $100.0M (+25% YoY); net loss ($2.7M) Q4; Adj. EBITDA ($5.0M) FY25.
- Submitted PMA-S to FDA for IGE indication expansion; NAUTILUS trial showed 77% median seizure reduction.
- Reiterated FY26 guidance: total rev $98-100M (20-22% RNS growth); Adj. EBITDA ($9-10M).
- DIXI Medical partnership ended Dec 31, 2025; discontinued ops reporting to begin Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000152828726000008/0001528287-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000152828726000008/npce-20260303.htm
  HTML page:      https://secwatch.observer/filing/0001528287-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer